Mushrooms (PDQ) – Health Professional Version: Polysaccharide-K (PSK) approval status (2024)

Peer-Reviewed Study · National Cancer Institute, PDQ Cancer Information Summaries · November 6, 2024

National Cancer Institute et al., 2024-11-06: NCI's PDQ summary on medicinal mushrooms states that PSK is an approved product used for cancer treatment in Japan, a proprietary Kureha formulation used since the mid-1970s, and separately that FDA has not approved any medicinal mushroom as a cancer treatment.

is an approved mushroom product used for cancer treatment in Japan. PSK is a proprietary formulation from the Kureha Corporation.

Health Professional version, Polysaccharide-K (PSK) section

National Cancer Institute et al., 2024-11-06: NCI's PDQ summary on medicinal mushrooms states that PSK is an approved product used for cancer treatment in Japan, a proprietary Kureha formulation used since the mid-1970s, and separately that FDA has not approved any medicinal mushroom as a cancer treatment. The approval is described, not evidenced: the summary cites no Japanese regulatory document. PDQ summaries exist only as web pages (no PDF edition), so pdf_url is empty by design; document_date is the date the posted summary was read, as the extract carries no visible last-modified date. Federal record; the approval detail (1976 registration, clinical use from 1977) is carried by CHG-22. Study type: review.